Nature Communications (Aug 2021)

SCOPE enables type III CRISPR-Cas diagnostics using flexible targeting and stringent CARF ribonuclease activation

  • Jurre A. Steens,
  • Yifan Zhu,
  • David W. Taylor,
  • Jack P. K. Bravo,
  • Stijn H. P. Prinsen,
  • Cor D. Schoen,
  • Bart J. F. Keijser,
  • Michel Ossendrijver,
  • L. Marije Hofstra,
  • Stan J. J. Brouns,
  • Akeo Shinkai,
  • John van der Oost,
  • Raymond H. J. Staals

DOI
https://doi.org/10.1038/s41467-021-25337-5
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 12

Abstract

Read online

Type III CRISPR-Cas systems recognize and cleave target RNAs and produce signalling molecules. Here the authors discover that both processes are governed by a flexible seed region, ultimately resulting in SCOPE, a SARSCoV-2 diagnostic assay with atto-molar sensitivity.